PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
 
J Psychiatry Neurosci. 2000 May; 25(3): 276–280.
PMCID: PMC1407723

Diltiazem as augmentation therapy in patients with treatment-resistant bipolar disorder: a retrospective study.

Abstract

OBJECTIVE: To examine the efficacy of a slow-release formulation of diltiazem as adjunctive therapy in patients with treatment-resistant bipolar disorder. DESIGN: Retrospective study. PATIENTS: Eight female patients with treatment-resistant bipolar disorder. INTERVENTIONS: Patients were administered diltiazem and monitored for a 6-month period before starting diltiazem and a 6-month period after starting the drug. OUTCOME MEASURES: All patients were seen at least monthly and usually every 2 weeks. The frequency and severity of both depressive and manic episodes were examined during the 6-month period after starting diltiazem, and compared with those during the 6-month period before diltiazem treatment. RESULTS: There was a statistically significant decrease in the frequency and severity of both manic and depressive episodes in these patients after they started treatment with diltiazem, compared with the period before they started treatment with diltiazem (p < 0.001). There was no evidence of side effects requiring patient withdrawal or of drug interactions. CONCLUSIONS: The results support previous suggestions that calcium-channel antagonists may be an effective adjunctive treatment in the management of bipolar disorder. Further controlled clinical studies are needed to confirm this small, open-label, retrospective study.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Dubovsky SL. Calcium antagonists in manic-depressive illness. Neuropsychobiology. 1993;27(3):184–192. [PubMed]
  • Höschl C. Do calcium antagonists have a place in the treatment of mood disorders? Drugs. 1991 Nov;42(5):721–729. [PubMed]
  • Giannini AJ, Houser WL, Jr, Loiselle RH, Giannini MC, Price WA. Antimanic effects of verapamil. Am J Psychiatry. 1984 Dec;141(12):1602–1603. [PubMed]
  • Höschl C, Kozený J. Verapamil in affective disorders: a controlled, double-blind study. Biol Psychiatry. 1989 Jan 15;25(2):128–140. [PubMed]
  • Garza-Treviño ES, Overall JE, Hollister LE. Verapamil versus lithium in acute mania. Am J Psychiatry. 1992 Jan;149(1):121–122. [PubMed]
  • Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropharmacol. 1990 Jun;13(3):224–228. [PubMed]
  • Grunze H, Walden J, Wolf R, Berger M. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Apr;20(3):419–426. [PubMed]
  • Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. 1993 Dec;49(3):257–272. [PubMed]
  • Goodnick PJ. Nimodipine treatment of rapid cycling bipolar disorder. J Clin Psychiatry. 1995 Jul;56(7):330–330. [PubMed]
  • Caillard V. Treatment of mania using a calcium antagonist--preliminary trial. Neuropsychobiology. 1985;14(1):23–26. [PubMed]
  • Chou JC. Recent advances in treatment of acute mania. J Clin Psychopharmacol. 1991 Feb;11(1):3–21. [PubMed]
  • Bowden CL. Role of newer medications for bipolar disorder. J Clin Psychopharmacol. 1996 Apr;16(2 Suppl 1):48S–55S. [PubMed]
  • Aoki K, Sato K, Kondo S, Yamamoto M. Hypotensive effects of diltiazem to normals and essential hypertensives. Eur J Clin Pharmacol. 1983;25(4):475–480. [PubMed]
  • Fabian JE, Silverstone PH. Diltiazem, a calcium antagonist, partly attenuates the effects of dextroamphetamine in healthy volunteers. Int Clin Psychopharmacol. 1997 Mar;12(2):113–120. [PubMed]
  • Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med. 1986 May;16(2):323–329. [PubMed]
  • De Beaurepaire R. Treatment of neuroleptic-resistant mania and schizoaffective disorders. Am J Psychiatry. 1992 Nov;149(11):1614–1615. [PubMed]
  • Lenzi A, Marazziti D, Raffaelli S, Cassano GB. Effectiveness of the combination verapamil and chlorpromazine in the treatment of severe manic or mixed patients. Prog Neuropsychopharmacol Biol Psychiatry. 1995 May;19(3):519–528. [PubMed]
  • Kennedy S, Ozersky S, Robillard M. Refractory bipolar illness may not respond to verapamil. J Clin Psychopharmacol. 1986 Oct;6(5):316–317. [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association